June 25, 2025
Intangible Assets

Actym Therapeutics Announces Issuance of US Patents

Actym Therapeutics has strengthened its IP portfolio with two newly issued patents covering its novel STACT™ biological platform technology and therapeutic agents utilizing the platform. BERKELEY, Calif., June 02, 2025–(BUSINESS WIRE)–Actym Therapeutics, a clinical-stage therapeutic product development and platform company, today announced the issuance of US patent Nos. 12,201,653 and 12,226,439 by the United States

Read More
Intangible Assets

Conduit Pharmaceuticals Receives U.S. Patent Approval For Its Lead Asset Targeting Autoimmune Diseases

Conduit secures a composition of matter patent from the USPTO for its lead asset, AZD1656, a Glucokinase Activator targeting autoimmune disorders, positioning the Company for clinical development and strategic partnerships. NAPLES, Fla. and CAMBRIDGE, United Kingdom, March 31, 2025 (GLOBE NEWSWIRE) — Conduit Pharmaceuticals Inc. (Nasdaq: CDT) (“Conduit Pharmaceuticals” or “Conduit” or the “Company”) today

Read More